Payment overview · 2025
General Payments
$1,026.32
51 reported records · 10 companies
Healthcare provider profile · identity verified
Timothy R Ausink
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · YAKIMA, WA · NPI 1760902365
Verified facts
What the public records show
CMS Open Payments records show Timothy R Ausink received $1,026.32 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $361.17 | 35.2% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $257.04 | 25.0% | 18 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $105.89 | 10.3% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $81.31 | 7.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.49 | 6.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $53.55 | 5.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.77 | 3.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.42 | 2.7% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $23.63 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.05 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,026.32 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $257.04 | 18 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $257.04 | 18 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $229.25 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $105.89 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.49 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.49 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $60.88 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.55 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.42 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 290 | 63 |
| Lisinopril | Lisinopril | 245 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 240 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 198 | 24 |
| Losartan Potassium | Losartan Potassium | 197 | 50 |
| Trazodone Hcl | Trazodone Hcl | 192 | 36 |
| Gabapentin | Gabapentin | 167 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 38 |
| Prednisone | Prednisone | 137 | 80 |
| Lamotrigine | Lamotrigine | 130 | 14 |
| Famotidine | Famotidine | 128 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 128 | 22 |
| Tramadol Hcl | Tramadol Hcl | 127 | 26 |
| Spironolactone | Spironolactone | 122 | 21 |
| Celecoxib | Celecoxib | 121 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 120 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 118 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 110 | 32 |
| Lorazepam | Lorazepam | 109 | 19 |
| Montelukast Sodium | Montelukast Sodium | 109 | 22 |
| Propranolol Hcl | Propranolol Hcl | 102 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 93 | 46 |
| Potassium Chloride | Potassium Chloride | 93 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 17 |
| Furosemide | Furosemide | 81 | 20 |
| Metformin Hcl | Metformin Hcl | 81 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 13 |
| Memantine Hcl | Memantine Hcl | 76 | 14 |
| Alprazolam | Alprazolam | 75 | 17 |
| Ozempic | Semaglutide | 71 | 13 |
| Topiramate | Topiramate | 70 | 20 |
| Azithromycin | Azithromycin | 68 | 51 |
| Meloxicam | Meloxicam | 67 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 15 |
| Farxiga | Dapagliflozin Propanediol | 60 | 14 |
| Pregabalin | Pregabalin | 60 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 57 | 11 |
| Chlorthalidone | Chlorthalidone | 55 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | 12 |
| Glipizide | Glipizide | 52 | 11 |
| Metformin Hcl Er | Metformin Hcl | 52 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Clonazepam | Clonazepam | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | suppressed |
| Simvastatin | Simvastatin | 49 | 12 |
| Ondansetron Odt | Ondansetron | 48 | 19 |
| Methocarbamol | Methocarbamol | 46 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 13 |
| Valacyclovir | Valacyclovir Hcl | 43 | 15 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 38 | suppressed |
| Allopurinol | Allopurinol | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 11 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 11 |
| Fluconazole | Fluconazole | 32 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 17 |
| Eliquis | Apixaban | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 19 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 11 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 13 |
| Diazepam | Diazepam | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Qvar Redihaler | Beclomethasone Dipropionate | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,026.32 · 51 records | AstraZeneca Pharmaceuticals LP | CAPLYTA, Cologuard Collection Kit, FARXIGA, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error